Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas(University of Pennsylvania), Judith Manola(Dana-Farber Cancer Institute), Robert G. Uzzo(Fox Chase Cancer Center), Keith T. Flaherty(Massachusetts General Hospital), Christopher G. Wood(The University of Texas MD Anderson Cancer Center), Christopher J. Kane(University of California, San Diego), Michael A.S. Jewett(Princess Margaret Cancer Centre), Janice P. Dutcher(Cancer Research Foundation), Michael B. Atkins(Vince Lombardi Cancer Clinic), Michael Pins(University of Illinois Chicago), George Wilding(The University of Texas MD Anderson Cancer Center), David Cella(Northwestern University), Lynne I. Wagner(Wake Forest University), Surena F. Matin(The University of Texas MD Anderson Cancer Center), Timothy M. Kuzel(Northwestern University), Wade J. Sexton(Moffitt Cancer Center), Yu-Ning Wong(Fox Chase Cancer Center), Toni K. Choueiri(Dana-Farber Cancer Institute), Роберто Пили(Indiana University – Purdue University Indianapolis), Igor Puzanov(Vanderbilt University), Manish Kohli(Mayo Clinic in Arizona), Walter M. Stadler(University of Illinois Chicago), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Robert Coomes(Patient Advocate Foundation), Robert S. DiPaola(Rutgers, The State University of New Jersey)
Cited by 636
Abstract
Related Papers
No related papers found
Powered by citation graph analysis